loading...
Del.icio.us
Google
Yahoo MyWeb
Facebook
BioVascular Overview
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.
BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in...More»
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.
BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007.
BioVascular’s second product utilizes a novel mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.«Less
Key People
Management
Board of Directors
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 02/2008 | Series C | 11M | Unknown |
Products
| Name: | Saratin |
| Product URL: | http://www.biovascularinc.com/saratin.html |
| Description: | Saratin is a 12 kDa polypeptide originally identified as a component of leech saliva (Hirudo medicinalis) and currently produced as a recombinant protein in yeast (Hansenula polymorpha). Saratin is designed to be applied during surgery to the endovascular surface where it coats the exposed collagen and inhibits vWF-dependent binding of platelets to arterial wall collagens. In preventing the vWF-mediated platelet adhesion to damaged vessels, saratin blocks the first step in a sequence of events involving platelet aggregation and activation and may thereby prevent the subsequent thrombus formation and intimal hyperplasia that occurs in a range of vascular surgical and endovascular procedures. |
Competitors
No competitors have been recorded yet. Add a competitor.
Related Companies
Profile
OpinionsUser Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | 7,770 | ||
Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.